The heterogeneity in inter-tumoral HDAC activity of human tumor samples might explain the poor response of HDAC inhibitors in clinics, suggesting their prudent usage after taking into account patient-to-patient epigenetic variation. This evidence concerns the gene HDAC9 and neoplasm.